Health TrialsbyHealthPanel

Systemic Organ Communication in STEMI

ConditionST-segment Elevation Myocardial Infarction (STEMI)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHeinrich-Heine University, Duesseldorf

About this trial

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.

Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients suffering from STEMI

Disqualifiers

< 18 years

Trial population

Patients suffering from STEMI

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • collection of clinical data

    Other intervention

    prospectively and systematically collection of clinical research data from STEMI patients

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Left-ventricular function

* LV-EF \< 40% at 6 months * Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months

Time frame
6 months
2

Left-ventricular remodeling

Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months

Time frame
6 months
3

Myocardial texture

* Infarct/Scar size \> 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months * remote zone ΔECV between day 5 of hospitalization and 6 months

Time frame
on day 5 of hospitalization and 6 months
4

Patency rate

Coronary patency rate

Time frame
6 months

Secondary outcomes

1

All cause mortaltiy

All cause mortaltiy

Time frame
12 months
2

MACCE

cardiovascular death, non-fatal stroke or myocardial infarction

Time frame
12 months
3

Re-Hospitalisation due to heart failure

Re-Hospitalisation due to heart failure

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Heinrich-Heine University, Duesseldorf

Lead sponsor

Source ClinicalTrials.gov
Apply now